Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Influenza virus vaccine - Seqirus

Next Previous
Search
Drug Profile

Influenza virus vaccine - Seqirus

Alternative Names: Cell-Based Quadrivalent Seasonal Influenza Vaccine (QIVc); FLUCELVAX; Flucelvax; Flucelvax Pediatric; FLUCELVAX QUAD; FLUCELVAX QUADRIVALENT; Flucelvax TETRA; Influenza vaccine (Flucelvax); Influenza vaccine (prepared in cell culture) - Seqirus; Optaflu; QIVc; TIVc

Latest Information Update: 29 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Seqirus
  • Class Influenza virus vaccines; Subunit vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 17 Oct 2024 The CHMP of the EMA recommends approval of influenza virus vaccine for Influenza virus infections (Prevention, In children, In adults) in the EU
  • 13 Feb 2024 Seqirus completes a phase III trial in Influenza virus infections (In children, In infants, Prevention) in Lativa, Bulgaria, Poland, Czech Republic, Estonia, Bangladesh, Honduras, Malaysia, New Zealand, Philippines, Romania, Thailand, Pakistan, South Africa, Ukraine (IM) (NCT03932682) (EudraCT2018-001857-29)
  • 15 Oct 2021 Launched for Influenza virus infections (In children, In infants, Prevention) in USA (IM)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top